COL7A1 and recessive dystrophic epidermolysis bullosa: In this respect, we have already demonstrated promising results with a COL7A1-targeting RTM capable of correcting ~40% of all RDEB-associated mutations encoded within the ~3300-nucleotide long target pre-mRNA [7].